Evidence map›Paper›PMID 37325663›Full record

ReviewFrontiers in immunology2023

Etiology, effects and management of comorbidities in multiple sclerosis: recent advances.

Ruth Ann Marrie, John D Fisk, Kathryn Fitzgerald, Kaarina Kowalec, Colleen Maxwell, Dalia Rotstein, Amber Salter, Helen Tremlett

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 3 pooled it
23.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Preventive strategies in neuroimmunology.Neurological research and practice · 2026
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Comorbidity and modifiable risk factors in multiple sclerosis.Therapeutic advances in neurological disorders · 2026
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 3 countries.

Ruth Ann MarrieDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
John D FiskNova Scotia Health and the Departments of Psychiatry, Psychology & Neuroscience, and Medicine, Dalhousie University, Halifax, NS, Canada.
Kathryn FitzgeraldDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Kaarina KowalecCollege of Pharmacy, University of Manitoba, Winnipeg, MB, Canada.
Colleen MaxwellSchools of Pharmacy and Public Health & Health Systems, University of Waterloo, Waterloo, ON, Canada.
Dalia RotsteinDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Amber SalterDepartment of Neurology, UT Southwestern, Dallas, TX, United States.
Helen TremlettDepartment of Medicine (Neurology) and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.
Dalhousie University · CAJohns Hopkins University · USKarolinska Institutet · SESt. Michael's Hospital · CAThe University of Texas Southwestern Medical Center · USUniversity of British Columbia · CAUniversity of Manitoba · CAUniversity of Waterloo · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Comorbid conditions commonly affect people with multiple sclerosis (MS). Population-based studies indicate that people with MS have an increased incidence of ischemic heart disease, cerebrovascular disease, peripheral vascular disease, and psychiatric disorders as compared to people without MS. People with MS from underrepresented minority and immigrant groups have higher comorbidity burdens. Comorbidities exert effects throughout the disease course, from symptom onset through diagnosis to the end of life. At the individual level, comorbidity is associated with higher relapse rates, greater physical and cognitive impairments, lower health-related quality of life, and increased mortality. At the level of the health system and society, comorbidity is associated with increased health care utilization, costs and work impairment. A nascent literature suggests that MS affects outcomes from comorbidities. Comorbidity management needs to be integrated into MS care, and this would be facilitated by determining optimal models of care.

Indexed as

Cerebrovascular DisordersMultiple SclerosisPeripheral Vascular DiseasesComorbidityHumansQuality of Lifecomorbidityepidemiologymodels of caremultiple sclerosisoutcomes

Identifiers

PMID37325663
PMCPMC10266935
OpenAlexW4378905377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.